Fairvalue-Calculator Fairvalue-Calculator
EN DE

Cue Biopharma, Inc (CUE) Fair Value & Analysis

Healthcare · US · Market cap $120M

Price$26.90
Fair Value$28.32
Upside+5.3%
Quality95/100
Evidence: Low Range $21.24 – $35.40

Fair value as of: Jun 24, 2026

Analysis

Cue Biopharma, Inc (CUE) currently trades at $26.90, while our model-based Fair Value estimate is $28.32 — implying the stock looks roughly 5.3% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a bifunctional fusion protein designed to promote immune tolerance by inducing iTregs from Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells. The company also develops CUE-101, which is in phase 1b clinical trial to treat HPV+ recurrent metastatic, or head and neck squamous cell carcinoma in second line, and beyond patients as a monotherapy, as well as in phase 1b clinical trial for the treatment of head and neck squamous cell carcinoma as a first line, therapy in combination with standard of care KEYTRUDA; and CUE-102, which is in phase 1b clinical trial as a monotherapy in late line recurrent metastatic WT1+ colorectal, gastric, ovarian, and…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Cue Biopharma, Inc (CUE) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $28.32 versus a price of $26.90 — about +5% (undervalued). Model-based estimate, not financial advice.
What is the fair value of CUE?
Our 21-model fair value for Cue Biopharma, Inc is $28.32 (as of Jun 24, 2026), built from audited fundamentals. The current price is $26.90.
What is the quality score of CUE?
Cue Biopharma, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.